Interleukin 13 (IL13) - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 61 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Interleukin 13 (IL13) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Interleukin 13 (IL13) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 13 (IL13) targeted pipeline therapeutics. 

The report provides comprehensive information on the Interleukin 13 (IL13) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 13 (IL13) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Interleukin 13 (IL13) 
- The report reviews Interleukin 13 (IL13) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Interleukin 13 (IL13) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Interleukin 13 (IL13) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Interleukin 13 (IL13) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Interleukin 13 (IL13) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 13 (IL13) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Interleukin 13 (IL13) Overview 7
Therapeutics Development 8
Interleukin 13 (IL13) - Products under Development by Stage of Development 8
Interleukin 13 (IL13) - Products under Development by Therapy Area 9
Interleukin 13 (IL13) - Products under Development by Indication 10
Interleukin 13 (IL13) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Interleukin 13 (IL13) - Products under Development by Companies 13
Interleukin 13 (IL13) - Products under Development by Universities/Institutes 15
Interleukin 13 (IL13) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Interleukin 13 (IL13) - Companies Involved in Therapeutics Development 23
Celgene Corporation 23
Cell Medica Limited 24
F. Hoffmann-La Roche Ltd. 25
GlaxoSmithKline Plc 26
MedImmune, LLC 27
Molecular Partners AG 28
Neovacs SA 29
Novartis AG 30
Sanofi 31
Interleukin 13 (IL13) - Drug Profiles 32
(dectrekumab + VAK-694) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
dectrekumab - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
lebrikizumab - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Monoclonal Antibody to Inhibit IL-4 and IL-13 for Atopic Dermatitis - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Monoclonal Antibody to Inhibit IL-5 and IL-13 for Asthma - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Recombinant Protein to Inhibit IL-13 and IL-17 for Respiratory Disease - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
RPC-4046 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
SAR-156597 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecules to Inhibit IL-13 for Ulcerative Colitis - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
tralokinumab - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
Interleukin 13 (IL13) - Dormant Projects 48
Interleukin 13 (IL13) - Discontinued Products 50
Interleukin 13 (IL13) - Featured News & Press Releases 51
Oct 13, 2016: Celgene to Present New Data on RPC4046 at UEGW and ACG Congresses 51
Feb 29, 2016: Roche provides update on two identical phase III studies of lebrikizumab in people with severe asthma 52
Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis 53
Aug 14, 2014: AstraZeneca advances tralokinumab to Phase III in severe asthma 53
May 12, 2014: AstraZeneca to present respiratory data on tralokinumab at ATS 2014 International Conference 54
Mar 05, 2014: Roche's lebrikizumab phase IIb data show reduction of asthma attack rates and improvement of lung function in adult patients with severe uncontrolled asthma 55
Aug 04, 2011: Roche's Investigational Treatment For Asthma Meets Primary Endpoint In Phase II Study 56
Apr 15, 2008: MedImmune Advances Asthma Program With Start Of A Phase 2 Trial In Europe And Australia And First U.S.-Based Clinical Trial For Antibody Targeting IL-13 57
Mar 18, 2008: MedImmune Advances Clinical Development Of Antibody Targeting Interleukin-9 In Patients With Asthma 58
May 25, 2005: Preclinical Data Support Link Between IL-9 And Airway Hyper-responsiveness Associated With Asthma 58
Appendix 60
Methodology 60
Coverage 60
Secondary Research 60
Primary Research 60
Expert Panel Validation 60
Contact Us 60
Disclaimer 61

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 20
Number of Products by Stage and Molecule Type, H2 2016 22
Pipeline by Celgene Corporation, H2 2016 23
Pipeline by Cell Medica Limited, H2 2016 24
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 25
Pipeline by GlaxoSmithKline Plc, H2 2016 26
Pipeline by MedImmune, LLC, H2 2016 27
Pipeline by Molecular Partners AG, H2 2016 28
Pipeline by Neovacs SA, H2 2016 29
Pipeline by Novartis AG, H2 2016 30
Pipeline by Sanofi, H2 2016 31
Dormant Projects, H2 2016 48
Dormant Projects (Contd..1), H2 2016 49
Discontinued Products, H2 2016 50